Based on these reports, we have previously investigated apoE interaction with N-terminal APP as a therapeutic target for AD and identified the binding site on apoE to N-terminal APP as corresponding to the low-density lipoprotein receptor (LDLR) binding domain (residues 133–152). This evidence concerns the gene APP and Alzheimer disease.